Not surprisingly, CMML shares molecular features with MDS and AML, especially therapy-related diseases, including loss or partial deletions of chromosome 7, rearrangement of the RUNX1 gene, mutations of RAS and PTPN11 [45]. This evidence concerns the gene RUNX1 and acute myeloid leukemia.